Funding
← Back to your selection

Superangels

Activity from announced rounds

Activity in this selectionOct 11, 2026 · Europe · Jan 1, 2026

Superangels is the Munich early-stage investor whose official portfolio identifies Sodex, Sedivention and sci2sci.

Recorded funding activity

Sodex develops construction-site technology. Sedivention develops a cryoablation treatment for obesity, while sci2sci manages research data and lineage. The firm remains distinct from its Growth Fund and unrelated Superangels namesakes.

Sources
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$9.4M
3 disclosed · full round size, not this investor’s share

By stage

Pre-seed1
Seed1
Undisclosed1

By primary sector

AI1
Healthtech1
Proptech1

By country

Germany2
Austria1

Rounds

3 in this selection
sci2sci

An AI data-governance platform for biotech and pharma that connects fragmented research and operational data, preserves its lineage and permissions, and grounds AI-assisted work in verifiable evidence.

€1.2MPre-Seed
Participant
Sodex Innovations

Developing AI-powered technology for construction sites, mines, and infrastructure projects

€4MUndisclosed
Role not disclosed
Sedivention

Develops minimally invasive one-time cryoablation therapy for obesity via balloon catheter

Role not disclosed